← Back to Clinical Trials
Recruiting NCT05093673

NCT05093673 Cerebellar Stimulation for Aphasia Rehabilitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05093673
Status Recruiting
Phase
Sponsor Johns Hopkins University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2021-10-25
Primary Completion 2027-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
Cathodal Cerebellar tDCSSemantic Feature Analysis (SFA)Sham

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2021-10-25 with a primary completion date of 2027-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The optimal site of neuromodulation for post-stroke aphasia has yet to be established. This study will investigate whether multiple sessions of cerebellar transcranial direct current stimulation (tDCS) boosts language therapy in helping people recover from aphasia as well as predict who is likely to respond to cerebellar tDCS.

Eligibility Criteria

Inclusion Criteria: * Chronic ischemic or hemorrhagic left hemisphere stroke * Fluent speaker of English by self-report * Age 18 or older * 6 months post onset of stroke * Diagnosis of aphasia and naming impairment using the Western Aphasia Battery-Revised Exclusion Criteria: * Lesion in the right cerebellum * Previous neurological disorder (other than stroke) affecting the brain, or any other neurodegenerative disorder or psychiatric disorder * Seizures during the previous 6 months * Uncorrected visual loss or hearing loss by self-report * Use of medications that lower the seizure threshold (e.g., methylphenidate) * Use of N-methyl-D-aspartate (NMDA) antagonists (e.g., memantine) * History of brain surgery or any metal in the head * Severely impaired auditory comprehension (lower than 2 on the Comprehension subscore on the Western Aphasia Battery-Revised) * Severely limited verbal output (lower than 2 on the Spontaneous Speech rating scale on the Western Aphasia Battery-Revised) * Individuals with severe claustrophobia, cardiac pacemakers or ferromagnetic implants, and pregnant women will be excluded from the MRI portion of the study.

Contact & Investigator

Central Contact

Rajani Sebastian, PhD

✉ rsebast3@jhmi.edu

📞 410-502-2445

Principal Investigator

Rajani Sebastian, PhD

PRINCIPAL INVESTIGATOR

Johns Hopkins University

Frequently Asked Questions

Who can join the NCT05093673 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05093673 currently recruiting?

Yes, NCT05093673 is actively recruiting participants. Contact the research team at rsebast3@jhmi.edu for enrollment information.

Where is the NCT05093673 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT05093673 clinical trial?

NCT05093673 is sponsored by Johns Hopkins University. The principal investigator is Rajani Sebastian, PhD at Johns Hopkins University. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology